Consolidated Income Statement

for the year ended 31 March 2009

  Notes 31 March
2009
€’000		 Before
Exceptional
Items
31 March
2008
€’000		 Exceptional
Items
31 March
2008
€’000		 Total
31 March
2008
€’000
           
Revenue, including share of joint ventures   510,488 441,436 - 441,436
Less: share of joint ventures’ revenue   (24,989) (20,040) - (20,040)
GROUP REVENUE 1 485,499 421,396 - 421,396
           
Operating expenses   (421,746) (297,560) - (297,560)
Distribution expenses   (20,529) (14,038) - (14,038)
Administrative expenses   (124,612) (68,309) - (68,309)
Other operating income 3 6,963 307 420,379 420,686
OPERATING (LOSS)/PROFIT BEFORE SHARE OF (LOSS)/PROFIT OF EQUITY ACCOUNTED INVESTEES   (74,425) 41,796 420,379 462,175
Share of (loss)/profit of equity accounted investees 15 (2,013) 580 - 580
OPERATING (LOSS)/PROFIT BEFORE FINANCING COSTS   (76,438) 42,376 420,379 462,755
           
Finance income 7 42,729 11,869 - 11,869
Finance costs 7 (19,657) (11,568) - (11,568)
NET FINANCING COSTS   23,072 301 - 301
           
(LOSS)/PROFIT BEFORE TAX   (53,366) 42,677 420,379 463,056
           
Income tax 8 7,731 (965) (76,225) (77,190)
(LOSS)/PROFIT FROM CONTINUING OPERATIONS   (45,635) 41,712 344,154 385,866
Profit from discontinued operations (net of tax) 4 - - 672,443 672,443
(LOSS)/PROFIT FOR THE YEAR   (45,635) 41,712 1,016,597 1,058,309
           
Attributable to:          
Equity holders of the parent   (22,361) 40,410 790,399 830,809
Minority interest   (23,274) 1,302 226,198 227,500
(LOSS)/PROFIT FOR THE YEAR   (45,635) 41,712 1,016,597 1,058,309
           
(Loss)/earnings per share – basic (cent)          
- continuing operations   (10.5)     166.5
- discontinued operations   -     193.3
- total 10 (10.5)     359.8
(Loss)/earnings per share – diluted (cent)          
- continuing operations   (10.5)     162.7
- discontinued operations   -     188.9
- total 10 (10.5)     351.6

 

The accompanying notes form an integral part of these financial statements.

 

 

On behalf of the Board

 

Tom Roche

Chairman

Jim Barry

Chief Executive


Approved by the Directors on 16 July 2009